BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Liu Y. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future. World J Gastroenterol 2023; 29(34): 5020-5037 [PMID: 37753366 DOI: 10.3748/wjg.v29.i34.5020]
URL: https://www.wjgnet.com/1007-9327/full/v29/i34/5020.htm
Number Citing Articles
1
Bo Yang, Wei Gou, Naiying Lan, Qing Shao, Weifeng Hu, Cheng Xue, Nanmei Liu. Tislelizumab induced dual organs dysfunction in a patient with advanced esophageal squamous cell carcinoma: a case reportFrontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1347896
2
Mohamed Wishahi. Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent conceptWorld Journal of Hepatology 2024; 16(4): 490-493 doi: 10.4254/wjh.v16.i4.490